Prevention of neurological disease in later life

Journal of Neurology Neurosurgery and Psychiatry

Volumn 63, Issue SUPPL. 1, 1997, Pages

  Rudd, Anthony G ^a,b   Wolfe, Charles D A ^b   Howard, Robin S ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN;

BLOOD PRESSURE; CAROTID ARTERY OBSTRUCTION; CONFERENCE PAPER; DEMENTIA; DIABETES MELLITUS; ENVIRONMENTAL FACTOR; EPILEPSY; FAMILY HISTORY; HEAD INJURY; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MENINGITIS; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OBESITY; PARKINSON DISEASE; POLIOMYELITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; SOCIAL STATUS; STROKE; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM;

EID: 0030669610     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.63.2008.39s     Document Type: Conference Paper

References (175)

1. Office of Population Censuses and Surveys. Mortality statistics DH2 (No 20) 1993. London: HMSO, 1996.
2. Office of Population Censuses and Surveys. Morbidity statistics from general practice 1991-2. London: HMSO, 1995.
3. Office of Population Censuses and Surveys. Communicable disease statistics 1993. London: HMSO, 1995. (Series MB2 No 20.)
4. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the multiple risk factors intervention trial. Circulation 1990;82:1616-28.
5. Wolf PA, Kannel WB, Cupples LA, D'Agostino. Update on epidemiology of stroke. In: F Clifford Rose, ed. Stroke: epidemiological, therapeutic and socio-economic aspects. London: Royal Society of Medicine, 1986:3-9. (International congress and symposium series No 99.)
6. Robins M, Baum H. Incidence. Stroke 1981;12(suppl 1):1-45.
7. Oxfordshire community stroke project. Incidence of stroke in Oxfordshire: first year's experience of a community stroke register. BMJ 1983;287:713-7.
8. Malmgren R, Bamford J, Warlow C, Sandercock P, Slattery J. Projecting the number of patients with first ever strokes and patients newly handicapped by stroke in England and Wales. BMJ 1989;298:656-60.
9. Bamford J, Sandercock P, Dennis M, et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire community stroke project 1981-6. I. Methodology, demography and incident cases of first ever stroke. J Neurol Neurosurg Psychiatry 1988;51:1373-80.
10. Barker DJP. The foetal and infant origins of inequalities in health in Britain. J Public Health Med 1991;13:64-8.
11. Robinson RJ. Is the child father of the man? BMJ 1992;304: 789-90.
12. Barker DJP, Osmond C. Death rates from stroke in England and Wales predicted from past maternal mortality. BMJ 1987;295:83-6.
13. Khaw K, Barrett-Connor E. Family history of stroke as an independent predictor of ischaemic heart disease in men and stroke in women. Am J Epidemiol 1986;123:59-66.
14. Welin L, Svardsudd K, Wilhelmson L, Larssson B, Tibblin G. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987;317:521-6.
15. De Faire U, Friberg L, Lundman T. Concordance for mortality with special reference to ischaemic heart disease and cerebrovascular disease. Preventive Med 1975;4:509-17.
16. Bromberg JEC, Rinkel GJE, Algra A, et al. Subarachnoid haemorrhage in first and second degree relatives of patients with subarachnoid haemorrhage. BMJ 1995;311:288-9.
17. Acheson RM, Sanderson C. Strokes: social class and geography. Popul Trends 1978;13-7.
18. WW Holland, project director. European Community atlas of avoidable deaths. 2nd ed. Oxford: Oxford University Press, 1991.
19. Shaper AG, Phillips AN, Pocock SJ, Walker M, Macfarlane PW. Risk factors for stroke in middle aged British men. BMJ 1991;302:1111-5.
20. Comstock GW. An epidemiologic study of blood pressure levels in a bi-racial community in the southern United States. Am J Hygiene 1957;65:271.
21. Otten MW, Teutch SM, Williams DF, Mark JS. The effect of known risk factors on the excess mortality of black adults in the United States. JAMA 1990;263:845-50.
22. Fray J, Douglas J. Pathophysiology of hypertension in blacks. Oxford: Oxford University Press, 1993.
23. Deubner DC, Tyroler HA. Attributable risk, population attributable risk and population attributable fraction of death associated with hypertension in a biracial population. Circulation 1975;52:901-8.
24. Gaines SK, Burke G, for the SECORDS Investigation. Ethnic differences in stroke: black-white differences in the United States population. Neuroepidemiology 1995;14:209-39.
25. Kittner SJ, White LR, Losonczy KG, Wolf PA, Hebel JR. Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. JAMA 1990;264:1267-70.
26. Heyman A, Karp HR, Heyden S, et al. Cerebrovascular disease in the bi-racial population of Evans County, Georgia. Stroke 1971;2:509-18.
27. Klag MJ, Whelton PK, Coresh J, Grim CE, Kuller LH. The association of skin colour with blood pressure in US blacks with low socio-economic status. JAMA 1991;265:599-602.
28. Balarajan R. Ethnic differences in mortality from ischaemic heart disease and cerebrovascular disease in England and Wales. BMJ 1991;302:560-4.
29. Cruickshank FB, Beevers D, Osbourne V, Haynes R, Corlett J, Selby S. Heart attack, stroke, diabetes and hypertension in West Indians, Asians and whites in Birmingham, England. BMJ 1980;281:1108.
30. Marmot MG, Adelstein AM, Bulusu L. Lessons from the study of immigrant mortality. Lancet 1984;i:1455-8.
31. Chaturvedi N, McKeigue PM, Marmot MG. Resting and ambulatory blood pressure differences in Afro-Caribbeans and Europeans. Hypertension 1993;22:90-6.
32. Haines AP, Booroff A, Goldenberg E, Morgan P, Singh M. Blood pressure, smoking, obesity and alcohol consumption in black and white patients in general practice. J Hypertension 1987;1:39-46.
33. Shanket N, Cruickshank JK. Coronary artery disease: impact upon black and ethnic minority people. In: Hopkins A, Bahl V, eds. Access to health care for people from black and ethnic minorities. London: Royal College of Physicians, 1993.
34. Miller GJ, Kotecha S, Wilkinson WH, et al. Dietary and other characteristics relevant for coronary heart disease in men of Indian, West Indian, and European descent in London. Atherosclerosis 1988;70:63-72.
35. Howard G, Russell GB, Anderson R, et al. Role of social class in excess black stroke mortality. Stroke 1995;26:1759-63.
36. Haberman S, Capildeo R, Rose FC. The seasonal variation is mortality from cerebrovascular disease. J Neurol Sci 1981;52:25-36.
37. Knox EG. Meteorological associations of cerebrovascular disease mortality in England and Wales. J Epidemiol Community Health 1981;35:220-3.
38. Christie D. Stroke in Melbourne, Australia: an epidemiological study. Stroke 1981;12:467-9.
39. Barer D, Ebrahim S, Smith C. Factors influencing day to day incidence of stroke in Nottingham. BMJ 1984;289: 662.
40. Whisnant JP. The decline of stroke. Stroke 1984;15:160-8.
41. Reid DD, Hamilton PJS, McCarthey P, Rose G. Smoking and other risk factors for coronary heart disease in British civil servants. Lancet 1976;ii:979-84.
42. Reid DD, Hamilton PJS, McCarthey P, Rose G. Smoking and other risk factors for coronary heart disease in British civil servants. Lancet 1990;131:579-88.
43. Reid JL. Hypertension and the brain. Br Med Bull 1994;50: 371-80.
44. Kannel WB, Wolf PA. Inferences from secular trend analysis of hypertension control. Am J Public Health 1992;82:1593-5.
45. Bonita R, Beaglehole R. Increased treatment of hypertension does not explain the decline in stroke mortality in the United States, 1970-80. Hypertension 1989;13(suppl 1): 69-73.
46. MacMahon SW, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression bias. Lancet 1990;335:765-74.
47. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease part 2. Short-term reductions in blood pressure: overviews of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38.
48. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Public Health 1983;75:4-11.
49. Devereux RB, Casale PN, Walerson DC, et al. Cost-effectiveness of echocardiography and electrocardiography for detection of left ventricular hypertrophy in patients with systemic hypertension. Hypertens 1987;969-76.
50. Wolf PA, Dawber TR, Thomas HE, Kannell WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke. The Framingham study. Neurology 1978;28:973-7.
51. Wolf PA, Abbott RD, Kannell WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991;22:983-8.
52. Sherman DG, Hart RG, Easton D. The secondary prevention of stroke in patients with atrial fibrillation. Arch Neurol 1986;43:65-70.
53. Lowe GDO, Jaap AJ, Forbes CD. Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet 1983;i:784-6.
54. Sage JI, Van Uitert RL. Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke 1983;14:537-40.
55. Wolf P, Kannel WB, Verter J. Current status of risk factors for stroke. Neurol Clin 1983;1:317-43.
56. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation. N Engl J Med 1987;317: 669-74.
57. Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost-effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992;305:1457-60.
58. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991;84:527-39.
59. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Warfarin to prevent thromboembolism in chronic atrial fibrillation. Lancet 1989;i:670.
60. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
61. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.
62. Ezckowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
63. Albers GW, Sherman DG, Gress DR, Paulseth JE, Petersen P. Stroke prevention in nonvalvular atrial fibrillation: a review of prospective randomised trials. Ann Neurol 1991;30:511-8.
64. Kistler JP, Singer DE, Millenson MM, et al. Effect of low-intensity warfarin anticoagulation on the level of activity of the hemostatic system of patients with atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators (BAATAF). Stroke 1993; 24:1360-5.
65. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1989;i:175-9.
66. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II study. Lancet 1994;343:687-91.
67. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342: 1255-62.
68. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischaemia. N Engl J Med 1995;333:5-10.
69. Copenhagen AFASAK study. Placebo-controlled randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989;i:175-9.
70. Antiplatelet Trialists Collaboration (a). Collaborative overview of randomised trials of antiplatelet therapy. 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
71. Sandercock PAG, Warow CP, Jones LN, Starkey IR. Predisposing factors for cerebral infarction: The Oxfordshire community stroke project. BMJ 1989;298:75-80.
72. Harrison MJ. The haematocrit and cerebrovascular accidents. Presse Med 1983;12:3095-7.
73. European Carotid Surgery Trialists Collaborative Group. MRC European carotid surgery trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991;337:1235-43.
74. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445-53.
75. Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischaemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 1991;266:3289-94.
76. Dennis M, Warlow C. Strategies for stroke. BMJ 1991;303: 636-8.
77. Lambert M. Should carotid endarterectomy be purchased? Purchasers need a broader perspective. BMJ 1995;310: 317-8.
78. European Carotid Surgery Trialists Collaborative Group. Endarterectomy for moderate symptomatic carotid stenosis: interim results from the MRC European carotid surgery trial. Lancer 1996;347:1591-3.
79. Barnett HJ, Haines SJ. Carotid endarterectomy for asymptomatic carotid stenosis [editorial comment]. N Engl J Med 1993;328:276.
80. Irvine CD, Baird RN, Lamont PM. Endarterectomy for asymptomatic carotid artery stenosis. BMJ 1995;311: 1121-32.
81. Antiplatelet Trialists Collaboration. Secondary prevention of vascular events by prolonged antiplatelet therapy. BMJ 1988;296:320-31.
82. Dutch Transient Ischaemic Attack Trial Study Group. A comparison of two doses of aspirin (30 mg versus 283 mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 1991;325:1261-6.
83. SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-9.
84. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54.
85. Uchiyama S, Takeuchi H, Osawa M, et al. Platelet function in thrombotic cerebrovascular disorders. Stroke 1983;14: 511-7.
86. Albers GW. Role of ticlopidine for prevention of stroke. Stroke 1992;23:912-6.
87. Grotta JC, Norris JW, Kamm B. Prevention of stroke with ticlopidine: who benefits most? Neurology 1992;42:111-5.
88. CAPRTE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRTE). Lancet 1996;348:1329-39.
89. Antiplatelet Trialists Collaboration, (b) Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial potency by antiplatelet therapy. BMJ 1994;308:159-66.
90. Lowe GDO. Antithrombotic treatment and atrial fibrillation. BMJ 1992;305:1445-6.
91. Larsson B, Svardsudd K, et al. Abdominal adipose tissue distribution, obesity and risk of cardiovascular and death. BMJ 1984;288:1401-4.
92. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995;38:1061-8.
93. Kiers L, Davis SM, Larkins R, et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry 1992;55:263-70.
94. Syrjanen J, Valtonen VV, Hvanainen M, Kaste M, Huttunen JK. Preceeding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. BMJ 1988;296:1156-60.
95. Grau AJ, Buggle F, Heindl S, et al. Recent infection as a risk factor for cerebrovascular ischaemia. Stroke 1995;26:373-9.
96. Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15.
97. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PH, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
98. Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland homocysteine study. JAMA 1995;274:1526-33.
99. Serjeant GR. Sickle cell disease. Oxford: Oxford University Press, 1985.
100. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen E, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocadial infarction. N Engl J Med 1984;311:501-5.
101. Qizilbash N, Warlow CP, Mann J. Fibrinogen and lipids as risk factors for ischaemic stroke. A case control study [abstract]. J Neurol 1990;237:143.
102. Meade TW, Mellows S, Brozovic M. Haemostatic function and ischaemic heart disease: principle results of the Northwick Park study. Lancet 1986;i:533-7.
103. Hess D. Stroke associated with antiphospholipid antibodies. Stroke 1992;23:23-4.
104. Chakravarty KK, Byron MA, Webley M, Durkin CJ, al-Hillawi AH, Bodley R, Wozniak J. Antibodies to cardiolipin in stroke: association with mortality and functional recovery in patients without systemic lupus erythematosus. Q J Med 1991;79:397-405.
105. Yiyohara Y, Ueda K, Hasuo Y, et al. Haematocrit as a risk factor of cerebral infarction: long-term prospective population survey in a Japanese rural community. Stroke 1986;17: 687-92.
106. Wannamethee AG, Shaper AG. Physical activity and stroke in British middle-aged men. BMJ 1992;304:597-601.
107. Kannel WB, Sorlie PD. Some health benefits of physical activity: the Framingham study. Arch Intern Med 1979;139: 857-61.
108. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. BMJ 1993;303:605-9.
109. Qizilbash N, Jones L, Warlow C, Mann J. Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor strokes. BMJ 1991;303:605-9.
110. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD. For the MRHT Research Group. Serum cholesterol levels and six years mortality from stroke in 350 977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989;320:904-10.
111. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989;298:789-94.
112. Camargo CA. Moderate alcohol consumption and stroke. The epidemiological evidence. Stroke 1989;20:1611-26.
113. Stampfer MJ, Colditz GC, Willet WC, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988; 319:267-73.
114. Kono S, Ikeda M, Tokudome S, Nishizumi M, Kuratsune M. Alcohol and mortality: a cohort study of male Japanese physicians. Int J Epidemiol 1986;15:527-32.
115. Klatsky AL, Armstrong MA, Friedman GD. Risk of cardiovascular mortality in alcohol drinkers, ex-drinkers and non-drinkers. Am J Cardiol 1990;66:1237-42.
116. Okada H, Horibe H, Ohno Y, Hayakawa N, Aori N. A prospective study of cerebrovascular disease in Japanese rural communities, Akabani and Asahi. Part I: Evaluation of risk factors in the occurrence of cerebral haemorrhage and thrombosis. Stroke 1976;7:599-607.
117. INTERSALT. An international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 1988;297:319-28.
118. Khaw K, Barrett-Connor E. Dietary potassium and stroke-associated mortality. N Engl J Med 1987;316:235-40.
119. Vessey MP, Lawless M, Yeates S. Oral contraception and stroke: findings in a large prospective study. BMJ 1984;289:530-1.
120. World Health Organisation. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 1996;348:498-505, 505-10.
121. Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992;48:276-308.
122. Grodstein FG, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
123. Acheson RM, William DRR. Does consumption of fruit and vegetables protect against stroke? Lancet 1983;i: 1191-3.
124. Farquhar JW, Fortmann SP, Flora JA, et al. Effects of community wide education on cardiovascular disease risk factors. The Stanford five-city project. JAMA 1990;264: 359-65.
125. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factors changes and mortality results. JAMA 1982;248:1465-78.
126. Meade TW, Berra A. Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992;48:276-308.
127. Puska P, Salonen JT, Nissinen A, et al. Change in risk factors for coronary heart disease during 10 years of a community intervention programme (North Karelia Project). BMJ 1983;287:1840-44.
128. World Health Organisation European Collaborative Group. European collaborative trial of multifactorial prevention of coronary heart disease: final report on the 6-year results. Lancet 1986;i:869-72.
129. Vartiainen E, Sarti C, Tuomilehto J, Kuulasmaa K. Do changes in cardiovascular risk factors explain changes in mortality from stroke in England? BMJ 1995;310:901-4.
130. Imperial Cancer Research Fund OXCHECK Study Group. Effectiveness of health checks conducted by nurses in primary care: results of the OXCHECK study after one year. BMJ 1994;308:308-12.
131. Family Heart Study Group. Randomised control trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. BMJ 1994;308:313-20.
132. Silagy C, Muir J, Coulter A, Thorogood M, Roe L. Cardiovascular risk and attitudes to life style: what do patients think? BMJ 1993;306:1657-60.
133. Meade TW, Brozovic M, Chakrabarti R, Haines AP, North WR, Stirling Y. Ethnic group comparisons of variables associated with ischaemic heart disease. Br Heart J 1978;40:789-95.
134. Neil HAN, Thompson AV, Thorogood M, et al. Diabetes in the elderly: the Oxford community diabetes study. Diabet Med 1989;6:608-13.
135. Macleod J, Edwards C, Bouchier I. Davidson's principles of medicine. Edinburgh: Churchill Livingstone, 1987.
136. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-86.
137. Office of Population Censuses and Surveys. Mortality statistics 1990. London: HMSO, 1991. (Series DH2 (17).)
138. Tiret L, Hausherr E, Thicoipe M, et al. The epidemiology of head trauma in Aquitane (France), 1986: a community-based study of hospital admissions and deaths. Int J Epidemiol 1990;19:133-40.
139. Thompson RS, Rivara FP, Thompson DC. A case-control study of the effectiveness of bicycle safety helmets. N Engl J Med 1989;320:1361-7.
140. Spicer RF. Adolescence. In: Holland WW, Detels R, Knox G, eds. Oxford textbook of public health. Oxford: Oxford University Press 1991.
141. Muller A. Business recession, alcohol consumption, drinking and driving laws: impact on Oklahoma motor vehicle fatalities and fatal crashes. Am J Public Health 1989;79: 1366-70.
142. West Midland Regional Health Authority. Public Health Report. Birmingham: WMRHA, 1991.
143. Tinnetti ME, Speechley M. Prevention of falls among the elderly. N Engl J Med 1989;320:1055-59.
144. A report of a working party of the Royal College of Physicians. Preventive medicine. London: Royal College of Physicians of London, 1991.
145. Faculty of Public Health Medicine. UK levels of health, first report. London: FPHM, 1991.
146. Department of Health. Health of the nation. Specification of national indicators. London: DH, 1992.
147. Writing Committee, Lancet Conference 1996. The challenge of the dementias. Lancet 1996;347:1303-7.
148. Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama study. Neurology 1995;45:1161-8.
149. Lee PN. Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology 1994;13:131-44.
150. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995;310: 970-3.
151. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913.
152. Evans JG. The epidemiology of the dementias in the elderly. In: Brody JA, Maddox GL, eds. Epidemiology and aging: an international perspective. New York: Springer, 1988: 36-53.
153. Katzman R. Vascular disease and dementia. In: Yahr M, ed. H Houston Merritt memorial volume. New York: Raven Press, 1983:153-76.
154. Ladurner G, Iliff LD, Lechner H. Clinical factors associated with dementia in ischaemic stroke. J Neurol Neurosurg Psychiatry 1982;45:97-101.
155. Gorelick PB, Brody JA, Cohen D, et al. Risk factors for dementia associated with multiple cerebral infarcts: a case-control analysis in predominantly African-American hospital-based patients. Arch Neurol 1993;50:714-20.
156. Tatemichi TK, Desmond DW, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol 1993;33:568-75.
157. Linet MS, Stewart WF, Celentano DD, Ziegler D, Sprecher M. An epidemiologic study of headache among adolescents and young adults. JAMA 1989;261:2211-6.
158. National Centre for Health Statistics. Advance data, vital and health statistics of the United States. Hyattsville, MD: National Center for Health Statistics, 1979. (DHEW, PHS Publication No 53.)
159. Lipton RB, Stewart WF. Epidemiology of migraine and other primary headache disorders. In: Gorelick PB, Alter M, eds. Handbook of neuroepidemiology. New York: Marcel Dekker, 1994.
160. Weinshenker BG, Rodriguez M. Epidemiology of multiple sclerosis. In: Gorelick PB, Alter M, eds. Handbook of neuroepidemiology. New York: Marcel Dekker, 1994:533-67.
161. Sibley WA, Banford CR, Clark K, Smith MS, Laguna JF. A prospective study of physical trauma and multiple sclerosis. J Neurol Neurosurg Psychiatry 1991;54:584-9.
162. Svenningsson A, Runmarker B, Lycke J, Andersen O. Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. Acta Neurol Scand 1990;82: 161-8.
163. Bansil S, Troiano R, Dowling PC, Cood SD. Measles vaccination does not prevent multiple sclerosis. Neuroepidemiology 1990;9:248-54.
164. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. New Engl J Med 1996;334: 71-6.
165. Martyn CN, Osmond C. Parkinson's disease and the environment in early life. J Neurol Sci 1995;132:201-6.
166. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994; 139:1129-38.
167. Hubble JP, Cao T, Hassanein RE, Neuberger JS, Koller WC. Risk factors for Parkinson's disease. Neurology 1993;43:1693-7.
168. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronaviruses in patients with Parkinson's disease. Neurology 1990;40(suppl 1):169.
169. Hubble J, Kjelstrom J, Beamann B, Koller W. Nocardia serology in Parkinson's disease. Mov Disord 1992;7:292.
170. Arman C. Motor neurone disease. In: Gorelick PB, Alter M, eds. Handbook of neuroepidemiology. New York: Marcel Dekker, 1994.
171. Arman C, Kurland LT, O'Brien PC, Mulder DW. Antecedent medical diseases in patients with amyotrophic lateral sclerosis: a population-based case-controlled study in Rochester, Minnesota, 1925-87. Arch Neurol 1991;48: 283-6.
172. Chancellor AM, Slartery JM, Fraser H, Warlow CP. Risk factors for motor neurone disease: a case-control study based on patients from the Scottish motor neuron disease register. J Neurol Neurosurg Psychiatry 1993;56:1200-6.
173. Hauser WA. Epidemiology of epilepsy. In: Gorelick PB, Alter M, eds. Handbook of neuroepidemiology. New York: Marcel Dekker, 1994.
174. Ramsay M, Gay N, Miller E, Rush M, et al. The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. CDR Review 1994;4: 12.
175. Nicolsi A. Epidemiology of bacterial meningitis and brain abscess. In: Gorelick PB, Alter M, eds. Handbook of neuroepidemiology. New York: Marcel Dekker, 1994.